AIDS Vaccine Advocacy Coalition Calls for Strategic Leadership and Urgency in the Implementation of Male Circumcision for HIV Prevention
Wednesday, March 28, 2007
New York, NY -- Mitchell Warren, Executive Director of the AIDS Vaccine Advocacy Coalition (AVAC) today issued the following statement regarding the new recommendations from the World Health Organization (WHO) and UNAIDS on male circumcision as an HIV prevention strategy.
"AVAC welcomes the new recommendations
from WHO and UNAIDS on the range of policy,
operational and ethical issues that will help
guide countries about where and how male
circumcision can be best implemented, promoted,
and safely performed. These normative
recommendations are essential to ensuring
successful rollout of male circumcision to
protect against HIV infection.
"Adding the offer of safe, sterile,
voluntary male circumcision to existing HIV
prevention programs could avert many infections
and save many lives. These programs could also
provide a new way to reach men and adolescent
boys who are frequently under-represented in
health clinics and HIV prevention
programs.
"As important as the new
recommendations are, though, they are only a
first step in translating research findings
into real public health impact. This
international guidance document must now be
complemented by funding, technical assistance
and operational research at the country level
to help national governments and health
ministries develop and implement policies and
programs to ensure that male circumcision is as
part of a comprehensive package of prevention
interventions.
"If these resources are not immediately
forthcoming, there is a real risk that the
benefits of male circumcision will be negated
by complications relating to unsafe surgeries
performed by unskilled practitioners seeking to
profit from demand, which is likely to increase
as news of these data spread through
communities around the world.
"It is also absolutely critical to
recognize the unanswered questions about male
circumcision, including: whether it is safe for
HIV-positive men and their partners; whether it
provides any protective benefit to women who
are sexual partners of circumcised,
HIV-positive men; and whether it has any
protective benefit in the context of anal sex.
"But not having all the answers should
not stop us from making the first big steps of
using the overall finding to help reduce new
infections. Making and resourcing clear plans
for filling in these gaps must be given equal
priority to rollout based on what we know
today.
"The benefits of male circumcision can
only be realized if male circumcision is
offered in programs that contain clear,
cultural and context-specific messages and that
explain the benefits and limitations of the
procedure for men and their sexual partners and
the importance of proper wound healing before
resuming sexual activity.
"Policymakers will face complex
decisions as they seek to implement these
recommendations. Decisions about targeting
high-risk men should be made with the utmost
care, and it is also essential that
circumcision not become falsely viewed as an
indicator of HIV-negative serostatus. Programs
must develop communications strategies and
packages of services that counter this
impression and meet the needs of HIV-negative
men, HIV-positive men, and especially their
partners.
"Research and dialogue are also needed
now to explore the feasibility of rolling out
infant circumcision. This approach will not
show immediate benefits in terms of HIV
incidence but can minimize risks and could be a
highly cost-effective implementation strategy
over the long term."
AVAC's report on understanding the
results of the male circumcision trials as well
as a detailed statement on research priorities
for male circumcision and advocacy fact sheets
for civil society in the US and in sub-Saharan
Africa are available at www.aidsvaccineclearinghouse.org/MC.
About AVAC: Founded in 1995, the AIDS
Vaccine Advocacy Coalition (AVAC) is a
non-profit, community- and consumer-based
organization that uses public education, policy
analysis, advocacy and community mobilization
to accelerate the ethical development and
global delivery of AIDS vaccines and other
prevention options.




